19 patients report seizure freedom with medical cannabis oil treatment for drug-resistant epilepsy: a case series

PurposeSeizure freedom (SF) is the primary goal of epilepsy treatment. More treatments that produce SF in drug-resistant epilepsy (DRE) are needed. Cannabis-based products for medicinal use (CBPMs) containing cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), administered as oils, have been shown...

Full description

Saved in:
Bibliographic Details
Main Authors: Frank Yizhao Chen, Joshua Myles Duckman, Brenden Samuel Rabinovitch, Katrin Julia Hannesson, Evan Cole Lewis
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Neuroscience
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fnins.2025.1570531/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850154708367310848
author Frank Yizhao Chen
Frank Yizhao Chen
Joshua Myles Duckman
Brenden Samuel Rabinovitch
Brenden Samuel Rabinovitch
Brenden Samuel Rabinovitch
Katrin Julia Hannesson
Evan Cole Lewis
Evan Cole Lewis
author_facet Frank Yizhao Chen
Frank Yizhao Chen
Joshua Myles Duckman
Brenden Samuel Rabinovitch
Brenden Samuel Rabinovitch
Brenden Samuel Rabinovitch
Katrin Julia Hannesson
Evan Cole Lewis
Evan Cole Lewis
author_sort Frank Yizhao Chen
collection DOAJ
description PurposeSeizure freedom (SF) is the primary goal of epilepsy treatment. More treatments that produce SF in drug-resistant epilepsy (DRE) are needed. Cannabis-based products for medicinal use (CBPMs) containing cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), administered as oils, have been shown to induce SF in DRE. However, there remains a paucity of published real-world evidence in both pediatrics and adults on SF resulting from CBPM therapy.MethodsThis is a retrospective case series at an outpatient neurology clinic in Toronto, Canada, on patients with DRE who experienced significant SF during CBPM treatment. All patients were treated via the clinic’s stepwise treatment protocol with CBPM oils only. The study describes clinical features of patients and their CBPM-related SF.ResultsWe report 19 DRE cases that experienced SF; 15 pediatric, 4 adults. The median cumulative SF duration was 245 days, split between continuous SF periods lasting at least 90 days. Five patients had continuous SF periods lasting ≥ 1 year. Most patients used CBD+THC regimens. Three patients weaned all concomitant ASMs. Adverse events (AEs) were reported by half of the patients.ConclusionThe results of the study support prioritizing CBPMs in cases of DRE. It also supports research into identifying clinical and biological biomarkers for DRE cases that may achieve SF under CBPM treatment. Lastly, the study supports improving the accessibility of CBPMs, using SF as a primary outcome in future CBPM epilepsy trials, and assessing the role of THC in reducing seizures.
format Article
id doaj-art-99814dc0ba804afebb04d570daf7564f
institution OA Journals
issn 1662-453X
language English
publishDate 2025-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Neuroscience
spelling doaj-art-99814dc0ba804afebb04d570daf7564f2025-08-20T02:25:13ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2025-05-011910.3389/fnins.2025.1570531157053119 patients report seizure freedom with medical cannabis oil treatment for drug-resistant epilepsy: a case seriesFrank Yizhao Chen0Frank Yizhao Chen1Joshua Myles Duckman2Brenden Samuel Rabinovitch3Brenden Samuel Rabinovitch4Brenden Samuel Rabinovitch5Katrin Julia Hannesson6Evan Cole Lewis7Evan Cole Lewis8North Toronto Neurology, Toronto, ON, CanadaDepartment of Research, JMCC Group, Toronto, ON, CanadaNorth Toronto Neurology, Toronto, ON, CanadaNorth Toronto Neurology, Toronto, ON, CanadaDivision of Experimental and Translational Neuroscience, Krembil Brain Institute, University Health Network, Toronto, ON, CanadaDepartment of Physiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, CanadaNorth Toronto Neurology, Toronto, ON, CanadaNorth Toronto Neurology, Toronto, ON, CanadaDepartment of Pediatrics, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, CanadaPurposeSeizure freedom (SF) is the primary goal of epilepsy treatment. More treatments that produce SF in drug-resistant epilepsy (DRE) are needed. Cannabis-based products for medicinal use (CBPMs) containing cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), administered as oils, have been shown to induce SF in DRE. However, there remains a paucity of published real-world evidence in both pediatrics and adults on SF resulting from CBPM therapy.MethodsThis is a retrospective case series at an outpatient neurology clinic in Toronto, Canada, on patients with DRE who experienced significant SF during CBPM treatment. All patients were treated via the clinic’s stepwise treatment protocol with CBPM oils only. The study describes clinical features of patients and their CBPM-related SF.ResultsWe report 19 DRE cases that experienced SF; 15 pediatric, 4 adults. The median cumulative SF duration was 245 days, split between continuous SF periods lasting at least 90 days. Five patients had continuous SF periods lasting ≥ 1 year. Most patients used CBD+THC regimens. Three patients weaned all concomitant ASMs. Adverse events (AEs) were reported by half of the patients.ConclusionThe results of the study support prioritizing CBPMs in cases of DRE. It also supports research into identifying clinical and biological biomarkers for DRE cases that may achieve SF under CBPM treatment. Lastly, the study supports improving the accessibility of CBPMs, using SF as a primary outcome in future CBPM epilepsy trials, and assessing the role of THC in reducing seizures.https://www.frontiersin.org/articles/10.3389/fnins.2025.1570531/fullepilepsycannabisCBD–cannabidiolTHC–tetrahydrocannabinolseizure freedompediatric epilepsy
spellingShingle Frank Yizhao Chen
Frank Yizhao Chen
Joshua Myles Duckman
Brenden Samuel Rabinovitch
Brenden Samuel Rabinovitch
Brenden Samuel Rabinovitch
Katrin Julia Hannesson
Evan Cole Lewis
Evan Cole Lewis
19 patients report seizure freedom with medical cannabis oil treatment for drug-resistant epilepsy: a case series
Frontiers in Neuroscience
epilepsy
cannabis
CBD–cannabidiol
THC–tetrahydrocannabinol
seizure freedom
pediatric epilepsy
title 19 patients report seizure freedom with medical cannabis oil treatment for drug-resistant epilepsy: a case series
title_full 19 patients report seizure freedom with medical cannabis oil treatment for drug-resistant epilepsy: a case series
title_fullStr 19 patients report seizure freedom with medical cannabis oil treatment for drug-resistant epilepsy: a case series
title_full_unstemmed 19 patients report seizure freedom with medical cannabis oil treatment for drug-resistant epilepsy: a case series
title_short 19 patients report seizure freedom with medical cannabis oil treatment for drug-resistant epilepsy: a case series
title_sort 19 patients report seizure freedom with medical cannabis oil treatment for drug resistant epilepsy a case series
topic epilepsy
cannabis
CBD–cannabidiol
THC–tetrahydrocannabinol
seizure freedom
pediatric epilepsy
url https://www.frontiersin.org/articles/10.3389/fnins.2025.1570531/full
work_keys_str_mv AT frankyizhaochen 19patientsreportseizurefreedomwithmedicalcannabisoiltreatmentfordrugresistantepilepsyacaseseries
AT frankyizhaochen 19patientsreportseizurefreedomwithmedicalcannabisoiltreatmentfordrugresistantepilepsyacaseseries
AT joshuamylesduckman 19patientsreportseizurefreedomwithmedicalcannabisoiltreatmentfordrugresistantepilepsyacaseseries
AT brendensamuelrabinovitch 19patientsreportseizurefreedomwithmedicalcannabisoiltreatmentfordrugresistantepilepsyacaseseries
AT brendensamuelrabinovitch 19patientsreportseizurefreedomwithmedicalcannabisoiltreatmentfordrugresistantepilepsyacaseseries
AT brendensamuelrabinovitch 19patientsreportseizurefreedomwithmedicalcannabisoiltreatmentfordrugresistantepilepsyacaseseries
AT katrinjuliahannesson 19patientsreportseizurefreedomwithmedicalcannabisoiltreatmentfordrugresistantepilepsyacaseseries
AT evancolelewis 19patientsreportseizurefreedomwithmedicalcannabisoiltreatmentfordrugresistantepilepsyacaseseries
AT evancolelewis 19patientsreportseizurefreedomwithmedicalcannabisoiltreatmentfordrugresistantepilepsyacaseseries